In a report released today, Matthew Gillmor from Robert W. Baird maintained a Buy rating on Athenahealth (NASDAQ: ATHN), with a price target of $160. The company’s shares closed yesterday at $146.75.
According to TipRanks.com, Gillmor is a 4-star analyst with an average return of 10.2% and a 59.1% success rate. Gillmor covers the Services sector, focusing on stocks such as Encompass Health Corporation, Cotiviti Holdings, and R1 RCM Inc.
Currently, the analyst consensus on Athenahealth is Moderate Buy and the average price target is $147.83, representing a 0.7% upside.
In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $158 price target.
See today’s analyst top recommended stocks >>
Athenahealth’s market cap is currently $5.93B and has a P/E ratio of 69.88. The company has a Price to Book ratio of 6.09.
Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
athenahealth, Inc. engages in the provision of cloud-based business services and mobile applications for medical groups and health systems. It offers network-based medical record, revenue cycle, patient engagement, care coordination, population health services, and other point-of-care mobile applications. The company was founded by Jonathan S.
